Diabetes Technology: Markers, Monitoring, Assessment, and Control of Blood Glucose Fluctuations in Diabetes

People with diabetes face a life-long optimization problem: to maintain strict glycemic control without increasing their risk for hypoglycemia. Since the discovery of insulin in 1921, the external regulation of diabetes by engineering means has became a hallmark of this optimization. Diabetes techno...

Full description

Bibliographic Details
Main Author: Boris P. Kovatchev
Format: Article
Language:English
Published: Hindawi Limited 2012-01-01
Series:Scientifica
Online Access:http://dx.doi.org/10.6064/2012/283821
id doaj-65a43227e62f4302a93f4ab0fef22ed6
record_format Article
spelling doaj-65a43227e62f4302a93f4ab0fef22ed62020-11-25T02:15:05ZengHindawi LimitedScientifica2090-908X2012-01-01201210.6064/2012/283821283821Diabetes Technology: Markers, Monitoring, Assessment, and Control of Blood Glucose Fluctuations in DiabetesBoris P. Kovatchev0Department of Psychiatry and Neurobehavioral Sciences, Department of Systems and Information Engineering, Center for Diabetes Technology, and University of Virginia Health System, University of Virginia, P.O. Box 400888, Charlottesville, VA 22908, USAPeople with diabetes face a life-long optimization problem: to maintain strict glycemic control without increasing their risk for hypoglycemia. Since the discovery of insulin in 1921, the external regulation of diabetes by engineering means has became a hallmark of this optimization. Diabetes technology has progressed remarkably over the past 50 years—a progress that includes the development of markers for diabetes control, sophisticated monitoring techniques, mathematical models, assessment procedures, and control algorithms. Continuous glucose monitoring (CGM) was introduced in 1999 and has evolved from means for retroactive review of blood glucose profiles to versatile reliable devices, which monitor the course of glucose fluctuations in real time and provide interactive feedback to the patient. Technology integrating CGM with insulin pumps is now available, opening the field for automated closed-loop control, known as the artificial pancreas. Following a number of in-clinic trials, the quest for a wearable ambulatory artificial pancreas is under way, with a first prototype tested in outpatient setting during the past year. This paper discusses key milestones of diabetes technology development, focusing on the progress in the past 10 years and on the artificial pancreas—still not a cure, but arguably the most promising treatment of diabetes to date.http://dx.doi.org/10.6064/2012/283821
collection DOAJ
language English
format Article
sources DOAJ
author Boris P. Kovatchev
spellingShingle Boris P. Kovatchev
Diabetes Technology: Markers, Monitoring, Assessment, and Control of Blood Glucose Fluctuations in Diabetes
Scientifica
author_facet Boris P. Kovatchev
author_sort Boris P. Kovatchev
title Diabetes Technology: Markers, Monitoring, Assessment, and Control of Blood Glucose Fluctuations in Diabetes
title_short Diabetes Technology: Markers, Monitoring, Assessment, and Control of Blood Glucose Fluctuations in Diabetes
title_full Diabetes Technology: Markers, Monitoring, Assessment, and Control of Blood Glucose Fluctuations in Diabetes
title_fullStr Diabetes Technology: Markers, Monitoring, Assessment, and Control of Blood Glucose Fluctuations in Diabetes
title_full_unstemmed Diabetes Technology: Markers, Monitoring, Assessment, and Control of Blood Glucose Fluctuations in Diabetes
title_sort diabetes technology: markers, monitoring, assessment, and control of blood glucose fluctuations in diabetes
publisher Hindawi Limited
series Scientifica
issn 2090-908X
publishDate 2012-01-01
description People with diabetes face a life-long optimization problem: to maintain strict glycemic control without increasing their risk for hypoglycemia. Since the discovery of insulin in 1921, the external regulation of diabetes by engineering means has became a hallmark of this optimization. Diabetes technology has progressed remarkably over the past 50 years—a progress that includes the development of markers for diabetes control, sophisticated monitoring techniques, mathematical models, assessment procedures, and control algorithms. Continuous glucose monitoring (CGM) was introduced in 1999 and has evolved from means for retroactive review of blood glucose profiles to versatile reliable devices, which monitor the course of glucose fluctuations in real time and provide interactive feedback to the patient. Technology integrating CGM with insulin pumps is now available, opening the field for automated closed-loop control, known as the artificial pancreas. Following a number of in-clinic trials, the quest for a wearable ambulatory artificial pancreas is under way, with a first prototype tested in outpatient setting during the past year. This paper discusses key milestones of diabetes technology development, focusing on the progress in the past 10 years and on the artificial pancreas—still not a cure, but arguably the most promising treatment of diabetes to date.
url http://dx.doi.org/10.6064/2012/283821
work_keys_str_mv AT borispkovatchev diabetestechnologymarkersmonitoringassessmentandcontrolofbloodglucosefluctuationsindiabetes
_version_ 1724897834129424384